Status:
COMPLETED
Bioequivalence Study of Divalproex Sodium 125 MG Delayed Release Tablets Under Fasting Conditions
Lead Sponsor:
Sandoz
Conditions:
Seizures
Eligibility:
MALE
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to demonstrate the bioequivalence of divalproex sodium 125 MG delayed release tablets.
Eligibility Criteria
Inclusion
- No clinically significant findings on physical examination, medical history or laboratory tests on screening
Exclusion
- Positive test for HIV or Hepatitis B and C
- History of sensitivity to valproic acid or related compounds
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2006
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT00864006
Start Date
October 1 2006
End Date
October 1 2006
Last Update
March 29 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.